![]() |
市場調查報告書
商品編碼
1503433
到 2030 年數位治療 (DTx) 市場預測:按產品、收益形式、銷售管道、應用和地區進行的全球分析Digital Therapeutics Market Forecasts to 2030 - Global Analysis By Offering, Revenue Modal, Sales Channel, Application and By Geography |
根據Stratistics MRC預測,2024年全球數位治療(DTx)市場規模將達到109.9億美元,並在預測期內以30.0%的複合年成長率成長,到2030年將達到530.2億美元。
數位療法 (DTx) 是基於軟體的干涉措施,旨在預防、管理和治療醫療狀況。與傳統藥物不同,DTx 透過行動應用、穿戴式裝置和虛擬實境等數位平台提供治療性介入。這些介入措施通常利用認知行為療法、正念技術和個人化演算法等元素來解決各種健康問題,例如精神健康障礙、慢性疾病和藥物濫用。 DTx 提供了一種可擴展、可存取且經濟高效的解決方案,使個人能夠在傳統醫療保健環境之外控制自己的健康。
根據國際糖尿病聯盟(IDF)糖尿病圖譜發布的2022年報告估計,2022年新增1型糖尿病病例中62.0%為20歲或以上。
醫療費用上漲
不斷上漲的醫療保健成本是推動數位治療(DTx)市場成長的主要因素。隨著傳統醫療保健成本持續上升,對經濟高效、易於使用的解決方案的需求日益成長。 DTx 提供了一種很有前景的選擇,它利用技術為各種疾病狀態提供基於證據的干涉措施,而成本僅為傳統治療的一小部分。由於具有透過遠端監控、個人化介入和改善患者治療結果來減少醫療保健支出的潛力,DTx 越來越被認為是控制醫療保健成本上升的關鍵因素。
資料隱私和安全問題
數位治療 (DTx) 市場中的資料隱私和安全問題圍繞著保護敏感患者資訊和確保治療資料的完整性。個人健康資料的收集和分析會增加違規風險,並可能導致潛在的剝削和身分盜竊。此外,保持機密性對於在患者和 DTx 提供者之間建立信任關係至關重要。需要強大的安全措施來防止未授權存取、偽造和洩露健康資料,並且必須遵守美國HIPAA(健康保險互通性和課責法案)和歐盟的 GDPR(通用資料保護條例)。
與穿戴式裝置和感測器整合
與穿戴式裝置和感測器的整合透過增強即時監控和個人化治療交付為數位治療 (DTx) 市場帶來了重大機會。透過與智慧型手錶和健身追蹤器等穿戴式裝置連接,DTx平台可以收集連續的生物辨識資料,從而實現更準確的健康狀況和治療調整。這種整合有利於遠端患者監控,並允許醫療保健提供者主動干預並根據患者的個人需求量身定做干涉措施。穿戴式裝置整合透過提供無縫的使用者體驗和即時回饋來促進患者的參與和依從性。
醫療保健差異和獲取機會
數位療法 (DTx) 的出現有望透過提供便利、可及和個人化的治療來徹底改變醫療保健服務。然而,對健康差異和准入的擔憂籠罩著這個快速成長的市場。 DTx 有潛力覆蓋廣泛的人群,包括服務不足的社區,但由於技術素養、智慧型手機和網路連線的使用以及社會經濟地位等因素,可能存在差異。
隨著人們尋求遠距醫療解決方案,COVID-19 大流行顯著加速了數位療法 (DTx) 的採用。在封鎖和社交距離措施的影響下,對包括數位治療在內的虛擬醫療服務的需求激增。此次疫情凸顯了對可近且便利的醫療保健選擇的需求,導致 DTX 市場的投資和創新增加。整合數位療法的遠端醫療平台迅速普及,為糖尿病、精神疾病和高血壓等慢性病提供個人化治療方案。
軟體/平台產業預計將在預測期內成為最大的產業
由於幾個關鍵因素,數位治療 (DTx) 市場的軟體/平台部分正在經歷強勁成長。數位健康解決方案和穿戴式裝置的日益普及增加了對促進 DTx 介入的軟體平台的需求。此外,人工智慧和機器學習演算法等技術的進步使得更複雜和個人化的數位治療解決方案的開發成為可能。此外,對預防性醫療保健的重視和慢性病盛行率的上升正在推動對數位療法的需求。
治療/護理相關應用預計在預測期內將經歷最高的複合年成長率
由於糖尿病、高血壓、肥胖等慢性病的盛行率不斷上升,數位治療(DTx)市場中與治療/護理相關的應用領域不斷成長,增加了對該領域提供的遠端監控和管理解決方案的需求我們正在經歷顯著的成長。科技的進步,特別是穿戴式裝置和行動醫療應用程式的進步,使得追蹤患者病情進展和提供個人化介入變得更加容易。此外,遠端醫療和虛擬護理模式的日益普及進一步支持了治療和護理相關 DTx 應用的擴展。
北美雷射加工市場的成長得益於幾個關鍵因素。科技的進步促進了更有效率、更精確的雷射加工系統的發展,這些系統擴大被汽車、電子和醫療保健等多種行業採用。該地區(尤其是美國)強勁的製造業正在推動切割、焊接和打標等應用中對雷射加工解決方案的需求。此外,業界對自動化和生產力提高的日益重視進一步推動了雷射加工技術的採用。此外,增加旨在增強雷射加工能力的研發活動的投資也有助於該地區的市場成長。
由於多種因素,亞太地區的雷射加工市場正在經歷顯著成長。特別是中國、日本、韓國等國家的製造業正快速成長,汽車、電子、醫療保健等各行業對雷射加工技術的需求不斷增加。此外,雷射技術的進步,包括精度和效率的提高,正在推動採用率。主要市場參與企業增加研發投資以及政府促進創新的措施進一步支持市場擴張。
According to Stratistics MRC, the Global Digital Therapeutics (DTx) Market is accounted for $10.99 billion in 2024 and is expected to reach $53.02 billion by 2030 growing at a CAGR of 30.0% during the forecast period. Digital therapeutics (DTx) are software-based interventions designed to prevent, manage, or treat medical conditions. Unlike traditional pharmaceuticals, DTx delivers therapeutic interventions through digital platforms such as mobile apps, wearables, or virtual reality. These interventions often leverage elements of cognitive behavioral therapy, mindfulness techniques, or personalized algorithms to address various health issues, including mental health disorders, chronic diseases, and substance abuse. DTx offers scalable, accessible, and cost-effective solutions, empowering individuals to take control of their health outside of traditional healthcare settings.
According to the 2022 report estimates published by the International Diabetes Federation (IDF) Diabetes Atlas, 62.0% of all new Type 1 Diabetes cases in 2022 were in people aged 20 years or older.
Rising healthcare costs
Rising healthcare costs serve as a major driver propelling the growth of the digital therapeutics (DTx) market. As traditional healthcare expenses continue to surge, there's a growing need for cost-effective and accessible solutions. DTx offers a promising alternative, leveraging technology to deliver evidence-based interventions for various medical conditions at a fraction of the cost of conventional treatments. With the potential to reduce healthcare expenditures through remote monitoring, personalized interventions, and improved patient outcomes, DTx are increasingly recognized as a vital component in the quest to curb escalating healthcare costs.
Data privacy and security concerns
Data privacy and security concerns in the digital therapeutics (DTx) market revolve around safeguarding sensitive patient information and ensuring the integrity of treatment data. With the collection and analysis of personal health data, there's a heightened risk of breaches, leading to potential exploitation or identity theft. Moreover, maintaining confidentiality is crucial to building trust between patients and DTx providers. Security measures must be robust to prevent unauthorized access, tampering, or leaks of health data, ensuring compliance with regulations like HIPAA (Health Insurance Portability and Accountability Act) in the U.S. and GDPR (General Data Protection Regulation) in the European Union.
Integration with wearable devices and sensors
Integration with wearable devices and sensors presents a significant opportunity in the digital therapeutics (DTx) market by enhancing real-time monitoring and personalized treatment delivery. By connecting with wearables like smartwatches and fitness trackers, DTx platforms can gather continuous biometric data, enabling more accurate health insights and treatment adjustments. This integration facilitates remote patient monitoring, allowing healthcare providers to intervene proactively and tailor interventions to individual patients needs. Wearable integration promotes patient engagement and adherence by offering a seamless user experience and real-time feedback.
Health inequities and access
The emergence of digital therapeutics (DTx) holds promise for revolutionizing healthcare delivery by offering convenient, accessible, and personalized treatments. However, there's a looming concern regarding health inequities and access within this burgeoning market. While DTx has the potential to reach a wide audience, including underserved communities, disparities may arise due to factors like technological literacy, access to smartphones or internet connectivity, and socioeconomic status.
The COVID-19 pandemic has significantly accelerated the adoption of digital therapeutics (DTx) as people seek remote healthcare solutions. With lockdowns and social distancing measures in place, there was a surge in demand for virtual healthcare services, including digital therapeutics. The pandemic highlighted the need for accessible and convenient healthcare options, leading to increased investment and innovation in the DTX market. Telemedicine platforms integrating digital therapeutics saw a rapid uptake, offering personalized treatment plans for chronic conditions like diabetes, mental health disorders, and hypertension.
The software/platforms segment is expected to be the largest during the forecast period
The software/platforms segment in the digital therapeutics (DTx) market has experienced robust growth due to several key factors. The increasing adoption of digital health solutions and wearable devices has propelled demand for software platforms that facilitate the delivery of DTx interventions. Additionally, advancements in technology, such as artificial intelligence and machine learning algorithms, have enabled the development of more sophisticated and personalized digital therapeutic solutions. Furthermore, the emphasis on preventive healthcare and the rising prevalence of chronic diseases have fueled the demand for digital therapeutics.
The treatment/care-related applications segment is expected to have the highest CAGR during the forecast period
The Treatment/Care-related Applications segment in the Digital Therapeutics (DTx) market has witnessed substantial growth due to the increasing prevalence of chronic diseases like diabetes, hypertension, and obesity has amplified the demand for remote monitoring and management solutions, which this segment provides. Advancements in technology, particularly in wearables and mobile health apps, have made it easier to track patient progress and deliver personalized interventions. Additionally, the rising adoption of telemedicine and virtual care models has further propelled the expansion of treatment- and care-related DTx applications.
The growth of the laser processing market in North America can be attributed to several key factors. Technological advancements have led to the development of more efficient and precise laser processing systems, increasing their adoption across various industries, including automotive, electronics, and healthcare. The region's robust manufacturing sector, particularly in the United States, has fueled demand for laser processing solutions for applications such as cutting, welding, and marking. Additionally, the rising emphasis on automation and productivity enhancement in industries has further propelled the uptake of laser processing technologies. Moreover, increasing investments in research and development activities aimed at enhancing laser processing capabilities have also contributed to market growth in the region.
The Asia-Pacific region's laser processing market has witnessed substantial growth due to several factors. The region's burgeoning manufacturing sector, particularly in countries like China, Japan, and South Korea, has driven the demand for laser processing technologies across various industries such as automotive, electronics, and healthcare. Additionally, advancements in laser technology, including improved precision and efficiency, have fuelled adoption rates. Increasing investments in research and development by key market players and government initiatives promoting technological innovation have further propelled market expansion.
Key players in the market
Some of the key players in Digital Therapeutics (DTx) market include Akili Interactive Labs, Biofourmis, Inc., Brain+ A/S, CureApp, Inc., DarioHealth, Fitbit Health Solutions, Gaia AG, Lark Health, LifeScan, Inc., Omada Health Inc, Otsuka Holdings Co., Ltd., Pear Therapeutics Inc, ResMed, Teladoc Health, Virta Health Corp and WellDoc, Inc.
In June 2024, Google recently introduced Fitbit Ace LTE - "a new, first-of-its-kind connected smartwatch for kids ages 7+. Ace LTE transforms exercise into play, while also giving families peace of mind with reliable calling, messaging and location sharing with parents." The company's VP of Product, Anil Sabharwal, said in a blog post.
In March 2024, Digital health company Welldoc has secured CE mark certification for its BlueStar mobile app, unlocking the advancement of its solutions in Europe. The app has been certified as a Class IIa medical device under the EU Medical Device Regulation.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.